Every material Form 8-K Rein Therapeutics, Inc. has filed with the SEC since May 04, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Rein Therapeutics published an investor presentation on its website on September 4, 2026, covering its LTI-03 candidate for idiopathic pulmonary fibrosis (IPF). The filing is a Regulation FD disclosure with no new financial results, and the presentation restates earlier trial data and says the RENEW Phase 2 trial is now enrolling.
Phase 1b trial: 10mg and 5mg doses were well tolerated with no treatment-related serious adverse events (SAEs).
Plasma surfactant protein D fell 4.6% over two weeks at the 10mg dose (p=0.111; exploratory).
Presentation says present cash may fund operations into the first quarter of 2028.
RENEW Phase 2 trial (NCT06968845) is now enrolling.
Rein Therapeutics received a Nasdaq notice on August 21, 2026, because its common stock closed below $1.00 per share over the previous 30 consecutive trading days. The company has until February 17, 2027 to regain compliance, and Nasdaq says it will start suspension and delisting procedures if compliance is not regained in time.
Notice received from Nasdaq on August 21, 2026 under Rule 5550(a)(1), the minimum $1.00 bid price standard
Compliance deadline is February 17, 2027, 180 days from the notice date
Regaining compliance requires a closing bid price of at least $1.00 for a minimum of 10 consecutive business days
Filing states there is no assurance of additional time after the initial 180-day period
Rein Therapeutics closed on May 4, 2026 the sale of 50,000,000 shares of common stock at $1.00 per share under an April 30 underwriting agreement with Konik Capital Partners, with net proceeds expected to be about $46.1 million. The company said the proceeds, with existing cash, are expected to fund operations into 2028 and its Phase 2 LTI-03 trial through completion. The offering adds shares outstanding and the filing also includes warrants to the underwriter and to Bios entities, which dilute existing shareholders.
50,000,000 shares sold at $1.00 per share before underwriting discounts; closed May 4, 2026
Expected net proceeds of about $46.1 million; underwriter has a 45-day option for up to 7,500,000 more shares
Underwriter warrants for up to 3% of shares sold, exercisable at $1.50 per share through April 30, 2031
Bios entities to receive warrants for 3,000,000 shares at $1.00 per share and defer conversion of 12,232 Series X preferred shares
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Rein Therapeutics, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →